Table 1.
Outcome of MGMT unmethylated glioblastoma
| Trial Name Experimental Regimen | Publication Year/Ref. | Median Overall Survival, mo |
||
|---|---|---|---|---|
| Standard Arm |
Experimental Arm |
|||
| TMZ/RT→TMZ | TMZ/RT + Novel Agent | RT + Novel Agent | ||
| EORTC 26981 | 20053 | |||
| RT alone | 12.6 | 11.8* | ||
| Glarius | 20149 | |||
| Beva/RT | 17.3 | 16.6 | ||
| EORTC 26082 | 20148 | |||
| Temsirolimus | 16 | 14.8 | ||
| CORE | 20157 | |||
| Cil (2×/wk)/TMZ/RT→Cil/TMZ | 13.4 | 16.3 | ||
| Cil (5×/wk)/TMZ/RT→Cil/TMZ | 14.5 | |||
| RTOG 0525† | 201214 | |||
| TMZ/RT→TMZ (21/28d) | 16.6 | 15.4 | ||
| RTOG 0825† | 201415 | |||
| Beva/TMZ/RT→beva/TMZ | 14.6 | 14.0 | ||
| AVAglio† | 201416 | |||
| Beva/TMZ/RT→beva/TMZ | 16.7 | 16.8 | ||
Abbreviations: Beva, bevacizumab; cil, cilengitide; RTOG, Radiation Therapy Oncology Group; AVAglio, Avastin in Glioblastoma.
†Subgroup of MGMT unmethylated tumors.
*RT alone.